A Novel Cutaneous Fatty Acid-Binding Protein-Related Signaling Pathway Leading to Malignant Progression in Prostate Cancer Cells

Genes and Cancer

Volumn 4, Issue 7-8, 2013, Pages 297-314

  Bao, Zhengzheng ^a   Malki, Mohammad I ^a   Forootan, Shiva S ^a   Adamson, Janet ^a   Forootan, Farzad S ^a   Chen, Danqing ^a   Foster, Christopher S ^a   Rudland, Philip S ^a   Ke, Youqiang ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

C FABP; fatty acid binding; PPAR ; prostate cancer; tumorigenicity

Indexed keywords

FATTY ACID; FATTY ACID BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; C FABP GENE; CANCER CELL; CANCER GROWTH; CARCINOGENICITY; CONTROLLED STUDY; FATTY ACID TRANSPORT; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUTANT; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; WILD TYPE;

EID: 84887425280     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913499155     Document Type: Article

References (51)

1. Masouye I,Saurat JH,Siegenthaler G.Epidermal fatty-acid-binding protein in psoriasis, basal and squamous cell carcinomas: an immunohistological study.Dermatology. 1996;192:208-13.
2. Bass NM.The cellular fatty acid binding proteins: aspects of structure, regulation, and function.Int Rev Cytol. 1988;111:143-84.
3. Celis JE,Ostergaard M,Basse B,et al.Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas.Cancer Res. 1996;56:4782-90.
4. Ostergaard M,Rasmussen HH,Nielsen HV,et al.Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation.Cancer Res. 1997;57:4111-7.
5. Jing C,Beesley C,Foster CS,et al.Identification of the messenger RNA for human cutaneous fatty acid-binding protein as a metastasis inducer.Cancer Res. 2000;60:2390-8.
6. Adamson J,Morgan EA,Beesley C,et al.High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity.Oncogene. 2003;22:2739-49.
7. Morgan EA,Forootan SS,Adamson J,et al.Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: potential prognostic marker and target for tumourigenicity-suppression.Int J Oncol. 2008;32:767-75.
8. Forootan SS,Bao ZZ,Forootan FS,et al.Atelocollagen-delivered siRNA targeting the FABP5 gene as an experimental therapy for prostate cancer in mouse xenografts.Int J Oncol. 2010;36:69-76.
9. Fang LY,Wong TY,Chiang WF,Chen YL.Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma.J Oral Pathol Med. 2010;39:342-8.
10. Fujii K,Kondo T,Yokoo H,Yamada T,Iwatsuki K,Hirohashi S.Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye.Proteomics. 2005;5:1411-22.
11. Ostergaard M,Rasmussen HH,Nielsen HV,et al.Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation.Cancer Res. 1997;57:4111-7.
12. Sinha P,Hutter G,Kottgen E,Dietel M,Schadendorf D,Lage H.Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas.Electrophoresis. 1999;20:2952-60.
13. Li Z,Huang C,Bai S,et al.Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach.Int J Cancer. 2008;123:2377-83.
14. Chen HJ,Treweeke AT,Ke YQ,West DC,Toh CH.Angiogenically active vascular endothelial growth factor is over-expressed in malignant human and rat prostate carcinoma cells.Br J Cancer. 2000;82:1694-701.
15. Jing C,Beesley C,Foster CS,et al.Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells.Cancer Res. 2001;61:4357-64.
16. Vorum H,Madsen P,Svendsen I,Cells JE,Honore B.Expression of recombinant psoriasis-associated fatty acid binding protein in Escherichia coli: gel electrophoretic characterization, analysis of binding properties and comparison with human serum albumin.Electrophoresis. 1998;19:1793-802.
17. Glatz JF,van Nieuwenhoven FA,Luiken J,Schaap F,van der Vusse G.Role of membrane-associated and cytoplasmic fatty acid-binding proteins in cellular fatty acid metabolism.Prostaglandins Leukot Essent Fatty Acids. 1997;57:373-8.
18. Kliewer SA,Xu HE,Lambert MH,Willson TM.Peroxisome proliferator-activated receptors: from genes to physiology.Recent Prog Horm Res. 2001;56:239-63.
19. Qi C,Zhu Y,Reddy JK.Peroxisome proliferator-activated receptors, coactivators, and downstream targets.Cell Biochem Biophys. 2000;32:187-204.
20. Sterchele PF,Sun H,Peterson RE,Vanden Heuvel JP.Regulation of peroxisome proliferator-activated receptor-alpha mRNA in rat liver.Arch Biochem Biophys. 1996;326:281-9.
21. Lemberger T,Saladin R,Vazquez M,et al.Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm.J Biol Chem. 1996;271:1764-9.
22. Braissant O,Foufelle F,Scotto C,Dauca M,Wahli W.Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.Endocrinology. 1996;137:354-66.
23. Chawla A,Barak Y,Nagy L,Liao D,Tontonoz P,Evans RM.PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation.Nat Med. 2001;7:48-52.
24. Segawa Y,Yoshimura R,Hase T,et al.Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer.Prostate. 2002;51:108-16.
25. Tolle A,Suhail S,Jung M,Jung K,Stephan C.Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma.BMC Cancer. 2011;11:302.
26. Furuhashi M,Hotamisligil GS.Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets.Nat Rev Drug Discov. 2008;7:489-503.
27. Storch J,Corsico B.The emerging functions and mechanisms of mammalian fatty acid-binding proteins.Annu Rev Nutr. 2008;28:73-95.
28. Pinthus JH,Lu JP,Bidaisee LA,et al.Androgen-dependent regulation of medium and long chain fatty acids uptake in prostate cancer.Prostate. 2007;67:1330-8.
29. Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.New Engl J Med. 2001;344:783-92.
30. Hanahan D,Weinberg RA.The hallmarks of cancer.Cell. 2000;100:57-70.
31. Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation.Cell. 2011;144:646-74.
32. Hudson TS,Perkins SN,Hursting SD,et al.Inhibition of androgen-responsive LNCaP prostate cancer cell tumor xenograft growth by dietary phenethyl isothiocyanate correlates with decreased angiogenesis and inhibition of cell attachment.Int J Oncol. 2012;40:1113-21.
33. Montecinos VP,Godoy A,Hinklin J,Vethanayagam RR,Smith GJ.Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma.PLoS One. 2012;7:e29623.
34. Weidner N,Carroll PR,Flax J,Blumenfeld W,Folkman J.Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.Am J Pathol. 1993;143:401-9.
35. Wang K,Peng HL,Li LK.Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis.Asian Pac J Cancer Prev. 2012;13:5665-9.
36. Bairati I,Meyer F,Fradet Y,Moore L.Dietary fat and advanced prostate cancer.J Urol. 1998;159:1271-5.
37. Kolonel LN,Nomura AM,Cooney RV.Dietary fat and prostate cancer: current status.J Natl Cancer Inst. 1999;91:414-28.
38. Epstein JI,Carmichael M,Partin AW.OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate.Urology. 1995;45:81-6.
39. Sonn GA,Aronson W,Litwin MS.Impact of diet on prostate cancer: a review.Prostate Cancer Prostatic Dis. 2005;8:304-10.
40. Kristal AR,Arnold KB,Neuhouser ML,et al.Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial.Am J Epidemiol. 2010;172:566-77.
41. Willett WC,Howe GR,Kushi LH.Adjustment for total energy intake in epidemiologic studies.Am J Clin Nutr. 1997;65:1220S-8S.
42. Gerber M.Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies.Br J Nutr. 2012;107:S228-39.
43. Albini A,Iwamoto Y,Kleinman HK,et al.A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987;47:3239-45.
44. Smith P,Rhodes NP,Shortland AP,et al.Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells.FEBS Lett. 1998;423:19-24.
45. Freedman VH,Shin SI.Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium.Cell. 1974;3:355-9.
46. Zwiebel JA,Davis MR,Kohn E,Salomon DS,Kidwell WR.Anchorage-independent growth-conferring factor production by rat mammary tumor cells.Cancer Res. 1982;42:5117-25.
47. Hagan RM,Worner-Gibbs J,Wilton DC.The interaction of liver fatty-acid-binding protein (FABP) with anionic phospholipid vesicles: is there extended phospholipid anchorage under these conditions?.Biochem J. 2008;410:123-9.
48. Janik P,Briand P,Hartmann NR.The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors.Cancer Res. 1975;35:3698-704.
49. Foster CS,Gosden CM,Ke YQ.Primer: tissue fixation and preservation for optimal molecular analysis of urologic tissues.Nat Clin Pract Urol. 2006;3:268-78.
50. Forootan SS,Foster CS,Aachi VR,et al.Prognostic significance of osteopontin expression in human prostate cancer.Int J Cancer. 2006;118:2255-61.
51. Forootan SS,Wong YC,Dodson A,et al.Increased Id-1 expression is significantly associated with poor survival of patients with prostate cancer.Hum Pathol. 2007;38:1321-9.